Anthony Altig - Assembly Biosciences Insider

ASMB -- USA Stock  

USD 35.04  0.63  1.83%

  Director
Mr. Anthony E. Altig is an Independent Director of Assembly Biosciences Inc. Mr. Altig joined our Board in January 2012. From 2008 to December 2017, Mr. Altig was the Chief Financial Officer of Biotix Holdings, Inc., a company that manufactures microbiological consumables, which was acquired by Mettler Toledo in September 2017. From 2004 to 2007, Mr. Altig served as the Chief Financial Officer of Diversa Corporationrationration, a public company developing specialized industrial enzymes. Prior to joining Diversa, Mr. Altig served as the Chief Financial Officer of Maxim Pharmaceuticals, Inc., a public biopharmaceutical company. In addition, Mr. Altig serves as a director and chairman of the audit committee for TearLab Corporationrationration, a publicly traded eyecare technology company. He formerly served as a director of MultiCell Technologies, Inc. and Optimer Pharmaceuticals, Inc., a pharmaceutical company, which was a public company until its acquisition by Cubist Pharmaceuticals, Inc. in October 2013
Age: 61  Director Since 2012      
317-210-9311  http://www.assemblybio.com
Altig received his B.B.A. in business from the University of Hawaii at Manoa and is a Certified Public Accountant . Among other experiences, qualifications, attributes and skills, Mr. Altig?s extensive management experience and financial expertise, as well as his experience serving on the boards of directors of several public pharmaceutical and healthcare companies, led to the conclusion of our Board that he should serve as a director of the Company in light of our business and structure.

Anthony Altig Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (32.32) % which means that it has lost $32.32 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (80.11) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives

DIRECTOR Since

Rosemary CraneEdge Therapeutics
2017
Robert TothDelMar Pharmaceuticals
2013
Dennis CarsonDynavax Technologies Corporatio
1997
Jennifer WengChina Cord Blood Corporation
N/A
Nancy WysenskiDova Pharmaceuticals
2018
Calvin RobertsAuris Medical Holding AG
2015
Anders HoveEdge Therapeutics
2015
Lynda CranstonDelMar Pharmaceuticals
2015
Saiid ZarrabianDelMar Pharmaceuticals
2018
Laura BregeDynavax Technologies Corporatio
2015
Robert RosenNantKwest
N/A
Stanley PlotkinDynavax Technologies Corporatio
2005
Kevin BuchiDicerna Pharmaceuticals
2018
Brian HalakDicerna Pharmaceuticals
2010
Alfred NovakDova Pharmaceuticals
2017
Colin GoddardEndocyte
2013
Jay FlatleyDenali Therapeutics
2015
John BellDelMar Pharmaceuticals
2013
Michael BlaszykNantKwest
2015
Peter KleinDenali Therapeutics
2018
Albert ChenChina Cord Blood Corporation
N/A

Entity Summary

Assembly Biosciences, Inc. operates as a clinical stage biotechnology company. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana. Assembly Biosciences operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 89 people.Assembly Biosciences (ASMB) is traded on BATS Exchange in USA. It is located in NEW YORK U.S.A and employs 89 people. Assembly Biosciences was previously known as ASSEMBLY BIOSCIENCES INC and was traded on BATS Exchange under the symbol VTUS. Assembly Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Assembly Biosciences Leadership Team

Uri Lopatin, Vice President - Research & Development, Chief Medical Officer
Helen Kim, Independent Director
Myron Holubiak, Independent Director
Lee Arnold, Chief Scientific Officer
Jacqueline Papkoff, Senior Vice President Chief Scientific Officer Microbiome
Anthony Altig, Independent Director
Richard Colonno, Chief Scientific Officer
Graham Cooper, CFO, COO and Principal Financial Officer and Principal Accounting Officer
William Ringo, Non-Executive Chairman of the Board
Susan Mahony, Director
Richard DiMarchi, Director
Miguel Barbosa, Chief Scientific Officer, Head of Microbiome Program
Thomas Rollins, Chief Development Officer
Mark Auerbach, Independent Director
Derek Small, Co-Founder, CEO and President and Director
Alan Lewis, Director
David Barrett, CFO, COO

Stock Performance Indicators

Current Sentiment - ASMB

Assembly Biosciences Investor Sentiment

Most of Macroaxis users are presently bullish on Assembly Biosciences. What is your sentiment towards investing in Assembly Biosciences? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Assembly Biosciences Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Assembly Biosciences and China Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Companies Directory module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.
Search macroaxis.com